Zimbabwe has declined a significant American health deal valued at $367m (£272m) spanning five years due to Washington's insistence on sensitive biological samples.
This rejection was revealed after a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson has since stated that the United States was seeking genetic material for research and commercial purposes but refused to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further talks to find a deal acceptable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Background
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court halted a similar health funding agreement after concerns were filed about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral deals to enhance openness and accountability.
As per statements, 16 African countries have to date agreed to these new agreements, representing over $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data over an extended period, with no corresponding guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"In essence, our country would provide the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our population should a new pandemic arise."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting frameworks already established through the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation contributes its information, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing discussions with our US partners on how subsequent co-operation might be structured in a manner that respects the sovereignty and dignity of both nations."
Medical Community Reaction
Medical experts expressed it acknowledged the official position, but recommended that talks need to persist considering a large portion of the nation's HIV programmes depended on external financing.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," the group commented.
This impasse emphasises the continuing debate between accepting much-needed international aid and safeguarding national sovereignty in an increasingly data-driven world.